These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 11329752)

  • 1. Federal court strikes down compounding regulations.
    Harteker LR
    Am J Health Syst Pharm; 2001 Apr; 58(8):638, 640, 643. PubMed ID: 11329752
    [No Abstract]   [Full Text] [Related]  

  • 2. FDA, states discuss pharmacy compounding regulatory framework.
    Traynor K
    Am J Health Syst Pharm; 2013 Feb; 70(3):180, 182. PubMed ID: 23327976
    [No Abstract]   [Full Text] [Related]  

  • 3. The "Lists": What Do They Mean?
    Voliva J
    Int J Pharm Compd; 2016; 20(6):477-479. PubMed ID: 28339386
    [No Abstract]   [Full Text] [Related]  

  • 4. U.S. Food and Drug Administration List of Drugs NOT to be Used in Compounded Medications for Humans (The Negative List).
    Int J Pharm Compd; 2016; 20(6):457-458. PubMed ID: 28339383
    [No Abstract]   [Full Text] [Related]  

  • 5. Compounding pharmacies: before and after an inspection.
    Kulkarni D; Ricketts S
    Int J Pharm Compd; 2013; 17(5):358-62. PubMed ID: 24459779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Practice of Compounding, Associated Compounding Regulations, and the Impact on Dermatologists.
    Quertermous J; Desai S; Harper J; Lebwohl M; Torres A; Kircik LH
    J Drugs Dermatol; 2018 Jul; 17(7):s17-s22. PubMed ID: 30005109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IACP's 2016 Compounders on Capitol Hill Asks.
    Int J Pharm Compd; 2016; 20(4):294-296. PubMed ID: 28333674
    [No Abstract]   [Full Text] [Related]  

  • 8. The U.S. Food and Drug Administration responds to the International Academy of Compounding Pharmacists' outsourcing letter.
    Int J Pharm Compd; 2014; 18(3):208. PubMed ID: 25306767
    [No Abstract]   [Full Text] [Related]  

  • 9. Improving and enforcing compounding pharmacy practices to protect patients.
    Pegues DA
    Clin Infect Dis; 2006 Oct; 43(7):838-40. PubMed ID: 16941363
    [No Abstract]   [Full Text] [Related]  

  • 10. Compounding problems and compounding confusion: federal regulation of compounded drug products and the FDAMA circuit split.
    Boodoo JM
    Am J Law Med; 2010; 36(1):220-47. PubMed ID: 20481406
    [No Abstract]   [Full Text] [Related]  

  • 11. Battles over compounding from bulk drugs move forward.
    Clark A
    J Am Vet Med Assoc; 2005 Jul; 227(1):9-10. PubMed ID: 16013529
    [No Abstract]   [Full Text] [Related]  

  • 12. GMPs vs GCPs: manufacturing and compounding definitions.
    Allen LV
    Int J Pharm Compd; 2013; 17(5):356. PubMed ID: 24459778
    [No Abstract]   [Full Text] [Related]  

  • 13. Compounding interest: a tragedy caused by contaminated steroids turned the spotlight on compounding pharmacies.
    Hinkley KN
    State Legis; 2013 Jun; 39(6):22-3. PubMed ID: 23805443
    [No Abstract]   [Full Text] [Related]  

  • 14. Safety Standards in Pharmaceutical Compounding, Part 2: A Closer Look at Agency Information, Oversight, and Assistance.
    Greeson NM; Mixon W; Allan WC
    Int J Pharm Compd; 2020; 24(5):371-379. PubMed ID: 32886634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 2013 State Compounding Legislation Tracker.
    Miller DG
    Int J Pharm Compd; 2013; 17(5):375-8. PubMed ID: 24459782
    [No Abstract]   [Full Text] [Related]  

  • 16. Compounding pharmacy: old methods finding a new niche.
    Matheny C; Martin CM
    Consult Pharm; 2010 Jun; 25(6):357-63. PubMed ID: 20534406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Introduction to Quality Control in a Compounding Pharmacy.
    Allen LV
    Int J Pharm Compd; 2016; 20(6):481-484. PubMed ID: 28339387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. U.S. Food and Drug Administration Inspections: Guide to a Successful Outcome for 503A Sterile Compounding Pharmacies.
    Yoch D
    Int J Pharm Compd; 2017; 21(2):95-102. PubMed ID: 28346203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinguishing between compounding facilities and the development of the 503B bulk drug substance list.
    Gianturco SL; Mattingly AN
    J Am Pharm Assoc (2003); 2021; 61(1):e8-e11. PubMed ID: 32713748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Canadian drugs: panacea or problem?
    State Legis; 2004 Jun; 30(6):9. PubMed ID: 15179953
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.